Reference
1. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm
J. 2018;22:18-033
.
2. Hughes DA. Medication adherence-Key considerations for clinical
pharmacologists. Br J Clin Pharmacol. 2020;86(4):628-9.
3. Albassam A, Hughes DA. What should patients do if they miss a dose? A
systematic review of patient information leaflets and summaries of
product characteristics. Eur J Clin Pharmacol. 2021;77(2):251-60.
4. Srinivasan S, Ajmal M, Pecci C, Lassar T. Edoxaban in Cardiovascular
Disease Management: Review. Br J Clin Pharmacol. 2021. doi:
10.1111/bcp.15026.
5. Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of
Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits
Clotting Factor Xa. Clin Pharmacokinet. 2016;55(6):641-55.
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin
JL, et al. Edoxaban versus warfarin in patients with atrial
fibrillation. N Engl J Med. 2013;369(22):2093-104.
7. Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant
therapy: an intermittent dosing strategy. Hematology Am Soc Hematol Educ
Program. 2018;2018(1):412-7.
8. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication
adherence on risk of ischemic stroke, major bleeding and deep vein
thrombosis in atrial fibrillation patients using novel oral
anticoagulants. Curr Med Res Opin. 2018;34(7):1285-92.
9. Pham PN, Brown JD. Real-world adherence for direct oral
anticoagulants in a newly diagnosed atrial fibrillation cohort: does the
dosing interval matter? BMC Cardiovasc Disord. 2019;19(1):64.
10. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham
LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke
and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart
Assoc. 2016;5(2): e003074
11. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton
RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With
Valvular Heart Disease: executive summary: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2014;129(23):2440-92.
12. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,
et al. The 2018 European Heart Rhythm Association Practical Guide on the
use of non-vitamin K antagonist oral anticoagulants in patients with
atrial fibrillation. Eur Heart J. 2018;39(16):1330-93.
13. SAVAYSA [package insert]. Tokyo Japan DSC, LTD. 2019.
14. Lixiana [package insert]. Tokyo Japan: Daiichi Sankyo Europe
GmbH.; 2021.
15. Gu JQ, Guo YP, Jiao Z, Ding JJ, Li GF. How to Handle Delayed or
Missed Doses: A Population Pharmacokinetic Perspective. Eur J Drug Metab
Pharmacokinet. 2020;45(2):163-72.
16. Ding JJ, Zhang YJ, Jiao Z, Wang Y. The effect of poor compliance on
the pharmacokinetics of carbamazepine and its epoxide metabolite using
Monte Carlo simulation. Acta Pharmacol Sin. 2012;33(11):1431-40.
17. Saint-Marcoux F, Woillard JB, Monchaud C, Friedl J, Bocquentin F,
Essig M, et al. How to handle missed or delayed doses of tacrolimus in
renal transplant recipients? A pharmacokinetic investigation. Pharmacol
Res. 2015;100:281-7.
18. MacCannell D, Berger Z, East L, Mercuri E, Kirschner J, Muntoni F,
et al. Population pharmacokinetics-based recommendations for a single
delayed or missed dose of nusinersen. Neuromuscul Disord.
2021;31(4):310-8.
19. Wang CY, Jiao Z, Ding JJ, Yu EQ, Zhu GX. Remedial dosing
recommendations for delayed or missed doses of valproic acid in patients
with epilepsy based on Monte Carlo simulations. Epilepsy Behav.
2020;111:107265.
20. Liu XQ, Yin YW, Wang CY, Li ZR, Zhu X, Jiao Z. How to handle the
delayed or missed dose of rivaroxaban in patients with non-valvular
atrial fibrillation: model-informed remedial dosing. Expert Rev Clin
Pharmacol. 2021;14(9):1153-63.
21. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG.
Prevalence, age distribution, and gender of patients with atrial
fibrillation. Analysis and implications. Arch Intern Med.
1995;155(5):469-73.
22. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ,
Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and
management of atrial fibrillation developed in collaboration with the
European Association for Cardio-Thoracic Surgery (EACTS): The Task Force
for the diagnosis and management of atrial fibrillation of the European
Society of Cardiology (ESC) Developed with the special contribution of
the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J.
2021;42(5):373-498.
23. Song S, Kang D, Halim AB, Miller R. Population
pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and
bleeding from edoxaban treatment. J Clin Pharmacol. 2014;54(8):910-6.
24. Wang W, Hallow KM, James DA. A Tutorial on RxODE: Simulating
Differential Equation Pharmacometric Models in R. CPT Pharmacometrics
Syst Pharmacol. 2016;5(1):3-10.
25. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory
Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants:
A Systematic Review. Chest. 2017;151(1):127-38.
26. Samuelson BT, Cuker A. Measurement and reversal of the direct oral
anticoagulants. Blood Rev. 2017;31(1):77-84.
27. Cuker A, Siegal D. Monitoring and reversal of direct oral
anticoagulants. Hematology Am Soc Hematol Educ Program.
2015;2015:117-24.
28. Vranckx P, Valgimigli M, Heidbuchel H. The Significance of Drug-Drug
and Drug-Food Interactions of Oral Anticoagulation. Arrhythm
Electrophysiol Rev. 2018;7(1):55-61.
29. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A
novel user-friendly score (HAS-BLED) to assess 1-year risk of major
bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Chest. 2010;138(5):1093-100.
30. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining
clinical risk stratification for predicting stroke and thromboembolism
in atrial fibrillation using a novel risk factor-based approach: the
euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.